Quantum Leap Healthcare
3450 California Street
San Francisco
CA
94118
United States
16 articles about Quantum Leap Healthcare
-
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
6/28/2023
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ ("Quantum Leap") today announced that six patients have been dosed with Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial.
-
Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai's Novel RNA-based Liquid Biopsy Platform in Breast Cancer
3/30/2023
Exai Bio announced a collaboration agreement with Quantum Leap Healthcare Collaborative™ to broaden the use of Exai's novel, RNA-based liquid biopsy platform to monitor patients' treatment response and disease burden in the I-SPY 2 TRIAL.
-
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
3/13/2023
ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative (“Quantum Leap”) today announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer.
-
Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi's Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™
10/27/2022
Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi's SET2,3™ test for use in the I-SPY 2 TRIAL for patients with locally advanced breast cancer.
-
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
8/16/2022
ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative™ ("Quantum Leap") today announced that ALX Oncology's next generation CD47 blocker, evorpacept, has been selected for a new investigational treatment arm in the I-SPY-P1 TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer.
-
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI® (aviptadil) When Given by Mouth Inhalation in Critically Ill Patients with COVID-19
3/31/2022
Quantum Leap Healthcare Collaborative (QLHC) announced in collaboration with NRx Pharmaceuticals, Inc. (NRx), that the nebulized form of ZYESAMI ® (Aviptadil), in the I-SPY COVID Trial of Critical COVID-19 patients has been stopped.
-
I-SPY COVID Trial Suggests No Clinical Benefit from Addition of IC14 to Treatment of Critically Ill Patients with COVID-19
12/3/2021
Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been terminated.
-
NRx Pharmaceuticals and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ (Aviptadil) in the I-SPY COVID Trial
7/12/2021
NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP) and Quantum Leap Healthcare Collaborative ™ (Quantum Leap) have begun treating patients with inhaled ZYESAMIÔ (Aviptadil), in the I-SPY COVID Trial (NCT04488081).
-
Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
3/23/2021
-- Adaptive Platform Trial is Evaluating Drugs and Investigational Products in the Treatment of Critically Ill COVID-19 Patients --
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
-
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial
1/11/2021
NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG, and the Quantum Leap Healthcare Collaborative of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ in the I-SPY COVID-19 Clinical Trial.
-
Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers
9/8/2020
Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting
-
Quantum Leap Healthcare Collaborative Announces the Selection of Byondis' SYD985 in the I-SPY 2 TRIAL for Stage 2/3, High-Risk Breast Cancer
7/7/2020
Quantum Leap Healthcare Collaborative™ announced the initiation of an investigational treatment arm with Byondis' [vic-]trastuzumab duocarmazine in the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.
-
Quantum Leap Healthcare's I-SPY 2 Investigators, ARDS Experts and COVID R&D Consortium Unite to Bring Success from the I-SPY Adaptive Platform Clinical Trial to COVID-19 ARDS ICU Patients
4/28/2020
Quantum Leap Healthcare Collaborative (QLHC), a non-profit organization focused on uniting patient care and research, and sponsor of the adaptive platform I-SPY 2 Trial™, announced today a unique pre-competitive consortium created for an I-SPY COVID Trial to rapidly identify therapies to treat acute respiratory distress syndrome (ARDS) in critically ill COVID-19 patients.
-
KEYTRUDA's Recent Success in Triple-Negative Breast Cancer Validates I-SPY 2 Adaptive Platform Approach to Phase II Clinical Trials
8/7/2019
Quantum Leap Healthcare Collaborative (QLHC) joins Merck in acknowledging the promising data from the KEYNOTE-522 trial. Merck recently announced that the Phase 3 KEYNOTE-522 trial met a primary endpoint, demonstrating statistically significant improved rates of pathological complete response for KEYTRUDA